Palbociclib

About

Therapy type: Targeted therapy

Therapy strategy: CDK4/6 inhibition

Mappings

NCI Thesaurus: Palbociclib (ncit:C49176)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (2) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (2) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib
EMA (1) FDA (1) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
EMA (1) FDA (1) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
EMA (1) FDA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib